Literature DB >> 32060855

Mechanisms of left ventricular dyssynchrony: A multinational SPECT study of patients with bundle branch block.

Saara Sillanmäki1,2, Alessia Gimelli3, Shahzad Ahmad4, Saba Samir4, Tomi Laitinen1,2, Prem Soman5,6.   

Abstract

BACKGROUND: To better understand the mechanisms of left ventricular (LV) mechanical dyssynchrony (LVMD), we explored the relative contributions of QRS duration (QRSd), LV ejection fraction (EF), volumes and scar to LVMD measured by gated single-photon emission tomography in a population of consecutive patients with left bundle branch block (LBBB) and right bundle branch block (RBBB) compared to controls.
METHODS: Myocardial perfusion imaging studies of 275 LBBB and 83 RBBB patients from three centers were analyzed. LVMD was defined as an abnormal phase bandwidth or phase standard deviation. Hospital and gender-specific normal values were obtained from 172 controls.
RESULTS: The prevalence of LVMD was 85 and 40% in LBBB and RBBB, respectively. Ejection fraction, scar severity, and LBBB morphology independently explained 70% of variance seen in PhaseBW. Ejection fraction had the highest area under the curve (AUC 0.918) in the receiver operating characteristics analysis of LVMD with an optimal cut-off of 47% (sensitivity 73% and specificity 98%). Notably, QRSd was not predictive.
CONCLUSION: LV mechanical dysfunction plays a greater role than conduction abnormality in the genesis of LVMD, a finding that is intriguing in the context of contemporary literature which suggests that QRSd is the parameter that is most predictive of CRT response.

Entities:  

Keywords:  Physiology of LV/RV function; SPECT; dyssynchrony; heart failure

Mesh:

Year:  2020        PMID: 32060855     DOI: 10.1007/s12350-020-02054-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  2 in total

1.  Electrical and mechanical dyssynchrony in patients with right bundle branch block.

Authors:  Saara Sillanmäki; Sini Aapro; Jukka A Lipponen; Mika P Tarvainen; Tiina Laitinen; Marja Hedman; Hanna Hämäläinen; Tomi Laitinen
Journal:  J Nucl Cardiol       Date:  2018-08-24       Impact factor: 5.952

2.  LV Dyssynchrony Assessed With Phase Analysis on Gated Myocardial Perfusion SPECT Can Predict Response to CRT in Patients With End-Stage Heart Failure.

Authors:  Nasrin Azizian; Fereydoon Rastgou; Tahereh Ghaedian; Allahyar Golabchi; Behdad Bahadorian; Vida Khanlarzadeh; Zahra Azizian; Majid Haghjoo
Journal:  Res Cardiovasc Med       Date:  2014-11-25
  2 in total
  4 in total

1.  Predicting left ventricular dyssynchrony: Can nuclear cardiology bring us closer "In Sync"?

Authors:  Karen Kan; Lawrence M Phillips
Journal:  J Nucl Cardiol       Date:  2020-06-16       Impact factor: 5.952

2.  Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry.

Authors:  Keiichiro Kuronuma; Robert J H Miller; Yuka Otaki; Serge D Van Kriekinge; Marcio A Diniz; Tali Sharir; Lien-Hsin Hu; Heidi Gransar; Joanna X Liang; Tejas Parekh; Paul B Kavanagh; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Balaji K Tamarappoo; Damini Dey; Daniel S Berman; Piotr J Slomka
Journal:  Circ Cardiovasc Imaging       Date:  2021-07-20       Impact factor: 7.792

3.  Evaluation of dyssynchrony with nuclear cardiac imaging: New evidence for an old parameter.

Authors:  Riccardo Liga; Alessia Gimelli
Journal:  J Nucl Cardiol       Date:  2021-01-20       Impact factor: 3.872

4.  Prognostic Significance of Left Ventricular Dyssynchrony Assessed with Nuclear Cardiology for the Prediction of Major Cardiac Events after Revascularization.

Authors:  Hidesato Fujito; Shunichi Yoda; Takumi Hatta; Yusuke Hori; Misa Hayase; Masatsugu Miyagawa; Yasuyuki Suzuki; Naoya Matsumoto; Yasuo Okumura
Journal:  Intern Med       Date:  2021-06-12       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.